Search Results - Susanne Grond

Baricitinib provides rapid and sustained improvements in absolute EASI and SCORAD outcomes in adults with moderate-to-severe atopic dermatitis by Jacob P. Thyssen, Thomas Bieber, C. Elise Kleyn, Audrey Nosbaum, Susanne Grond, Helmut Petto, Elisabeth Riedl, Andreas Wollenberg

Connect to this object online.

Itch improvement has a major and comparable effect on the Dermatology Life Quality Index in psoriasis and atopic dermatitis patients by Wolf‐Henning Boehncke, Adam Reich, Sonja Ständer, Julio Hernandez, Can Mert, Susanne Grond, Maria Jose Rueda, Christopher Schuster, Gil Yosipovitch

Connect to this object online.

Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials by Saxon D. Smith, Alexandros Stratigos, Matthias Augustin, Jose Manuel Carrascosa, Susanne Grond, Elisabeth Riedl, Wen Xu, Himanshu Patel, Mark Lebwohl

Connect to this object online.

Factors Predicting Quality of Life Impairment in Adult Patients with Atopic Dermatitis: Results from a Patient Survey and Machine Learning Analysis by Carle Paul, Christopher E. M. Griffiths, Antonio Costanzo, Pedro Herranz, Susanne Grond, Can Mert, Nicole Tietz, Elisabeth Riedl, Matthias Augustin

Connect to this object online.

Real-World Treatment Patterns and Treatment Benefits among Adult Patients with Atopic Dermatitis: Results from the Atopic Dermatitis Patient Satisfaction and Unmet Need Survey by Matthias Augustin, Antonio Costanzo, Andrew Pink, Julien Seneschal, Christopher Schuster, Can Mert, Mariana Guerreiro, Nicole Tietz, Susanne Grond, Marjolein de Bruin-Weller

Connect to this object online.

Baricitinib Improvement Across Regions in Atopic Dermatitis Patients with Baseline Body Surface Area up to 40% and Severe Itch by José-Manuel Carrascosa, Alessandra Narcisi, Toshifumi Nomura, Sonja Ständer, Christian Vestergaard, Silvia Sabatino, Susanne Grond, Uffe Koppelhus, Mohamed Elrayes, Yun-Fei Chen, Chunyuan Liu, Andreas Wollenberg

Connect to this object online.

Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials by Thomas Bieber, Norito Katoh, Eric L. Simpson, Marjolein de Bruin-Weller, Diamant Thaçi, Antonio Torrelo, Angelina Sontag, Susanne Grond, Maher Issa, Xiaoyu Lu, Tracy Cardillo, Katrin Holzwarth, Jacob P. Thyssen

Connect to this object online.